Drug Trial Radar · NCT04501679
A Study to Assess the Efficacy and Safety of Nemolizumab (CD14152) in Participants With Prurigo Nodularis (PN)
Last checked: Nov 20, 2026Latest source record: Jul 10, 2024 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
274
Actual
Start
Aug 11, 2020
Primary completion
Mar 30, 2022
Study completion Mar 31, 2022
Sponsor
- Lead sponsor
- Galderma R&DIndustry
- Sponsor type
- Industry
- First posted
- Aug 6, 2020
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Double (participant, investigator)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The primary objective was to assess the efficacy of nemolizumab (CD14152) compared to placebo in participants greater than or equal to (\>=) 18 years of age with prurigo nodularis (PN) after a 16-week treatment period.
Conditions
- Prurigo Nodularis
Interventions
NemolizumabDrug
Participants received either 30 mg or 60 mg dose of nemolizumab as SC injection.
PlaceboDrug
Participants received matching placebo as SC injection.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Number of Participants With an Improvement of Greater Than or Equal to (>=) 4 From Baseline in Weekly Average Peak Pruritus Numeric Rating Scale (PP NRS) at Week 16Time frame: Baseline, Week 16
- Number of Participants With an Investigator Global Assessment (IGA) Success at Week 16Time frame: Baseline, Week 16
Locations
74 sites in 9 countries. Site status is shown where the registry gives one.
Galderma Investigational Site
Fountain Valley, California
Galderma Investigational Site
San Diego, California
Galderma Investigational Site
Washington D.C., District of Columbia
Galderma Investigational Site
Aventura, Florida
Galderma Investigational Site
Miami, Florida
Galderma Investigational Site
North Miami Beach, Florida
Galderma Investigational Site
Ormond Beach, Florida
Galderma Investigational Site
Chicago, Illinois
Galderma Investigational Site
Indianapolis, Indiana
Galderma Investigational Site
Louisville, Kentucky
Galderma Investigational Site
Boston, Massachusetts
Galderma Investigational Site
Saint Joseph, Michigan
Galderma Investigational Site
New York, New York
Galderma Investigational Site
Cincinnati, Ohio
Galderma Investigational Site
Dublin, Ohio
Galderma Investigational Site
Anderson, South Carolina
Galderma Investigational Site
Murfreesboro, Tennessee
Galderma Investigational Site
Dallas, Texas
Galderma Investigational Site
Dripping Springs, Texas
Galderma Investigational Site
Pflugerville, Texas
Galderma Investigational Site
Webster, Texas
Galderma Investigational Site
Morgantown, West Virginia
Galderma Investigational Site
Brussels, Belgium
Galderma Investigational Site
Ghent, Belgium
Galderma Investigational Site
Jette, Belgium
Galderma Investigational Site
Leuven, Belgium
Galderma Investigational Site
Liège, Belgium
Galderma Investigational Site
Bathurst, Canada
Galderma Investigational Site
Calgary, Canada
Galderma Investigational Site
London, Canada
Galderma Investigational Site
Markham, Canada
Galderma Investigational Site
North York, Ontario, Canada
Galderma Investigational Site
Bordeaux, France
Galderma Investigational Site
Brest, France
Galderma Investigational Site
Lille, France
Galderma Investigational Site
Nantes, France
Galderma Investigational Site
Nice, France
Galderma Investigational Site
Paris, France
Galderma Investigational Site
Paris, France
Galderma Investigational Site
Pierre-Bénite, France
Showing 40 of 74 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.